Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VINCENT: Obicetrapib and Evolocumab in Mild Dyslipidemia
NCT06496243Phase 2Recruiting
- Sponsor
- NewAmsterdam Pharma
- Start
- Dec 2024
- Primary completion
- Nov 2026
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of obicetrapib in dyslipidemia, sponsored by NewAmsterdam Pharma. Started Dec 2024; status: recruiting.
02
Drugs
obicetrapib
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT06496243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06496243.